0
     

Report Added
Report already added
Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

The global wound care biologics market is valued at an estimated USD 1.8billion in 2022 and is projected to reach USD 2.4billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such asthe growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market.

“The biological skin substitutes segment accounted for the highest growth rate in thewound care biologicsmarket, by product, during the forecast period”

The wound care biologics market is segmented into biological skin substitutes and topical agents. The biological skin substitutes is expected to register the highest growth rate during the forecast period. Factors such as the increasing burden of surgical & traumatic woundsand the increase in burn injuries arecontributing to the growth of this segment.

“Hospitalssegment accounted for the highest CAGR”

Based on end users, the wound care biologics market is segmented into hospitals, ambulatory surgery centers, and burn care centers & wound clinics. Hospitals segment is expected to register the highest CAGR during the forecast period. Extended hospital stays or readmissions of patients with chronic conditions have increased the adoption of various wound care biologic products. The increasing incidence of hospital-acquired wounds is a key growth driver for this market segment. Also, the adoption of wound care biologic products is higher in hospitals, owing to their higher purchasing power, highly skilled healthcare professionals, and access to technologically developed surgical facilities.

“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”

The global wound care biologics market is segmented into five regions - North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to witness the highest growth in the wound care biologics market during the forecast period. The high growth in this region can primarily be attributed to the increasing prevalence of diabetes, rising healthcare spending, growing per capita income, the expansion of private-sector hospitals to rural areas in various APAC countries, increasing medical tourism, and the presence of high-growth markets.The low labor costs and favorable regulatory environment in the region are also expected to propel market growth.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
•By Designation: C-level - 27%, D-level - 18%, and Others - 55%
•By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
•Smith & Nephew plc (UK)
•Organogenesis Inc. (US)
•MIMEDX (US)
•Integra LifeSciences (US)
•Stryker Corporation (US)
•Mölnlycke Health Care AB (Sweden)
•Vericel Corporation (US)
•Bioventus LLC (US)
•Anika Therapeutics, Inc. (US)
•AbbVie Inc. (US)
•Kerecis (Iceland)
•Marine Polymer Technologies, Inc. (US)
•Merakris Therapeutics (US)
•PolyMedics Innovations GmbH (Germany)
•FibrohealWoundcarePvt. Ltd. (India)
•Anamay Biotech, Inc. (India)
•Virchow Biotech Private Limited (India)
•Medline Industries, LP (US)
•Tides Medical (US)
•Viscus Biologics LLC (US)
•Stability Biologics (US)
•MTF Biologics (US)
•Skye Biologics Holdings, LLC (US)
•AlloSource (US)
•SurgiLogix (US)

Research Coverage:
This report provides a detailed picture of the global wound care biologics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, wound type, end user,and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall wound care biologics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, and opportunities.
Table of Contents

1INTRODUCTION27
1.1OBJECTIVES OF THE STUDY27
1.2MARKET DEFINITION27
1.2.1INCLUSIONS AND EXCLUSIONS OF THE STUDY28
1.2.2MARKETS COVERED28
FIGURE 1WOUND CARE BIOLOGICS MARKET28
1.2.3YEARS CONSIDERED FOR THE STUDY29
1.3CURRENCY29
1.4LIMITATIONS29
1.5STAKEHOLDERS30
1.6SUMMARY OF CHANGES30
2RESEARCH METHODOLOGY31
2.1RESEARCH DATA31
2.2RESEARCH APPROACH31
FIGURE 2WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY31
2.2.1SECONDARY DATA32
2.2.1.1Key data from secondary sources32
2.2.2PRIMARY DATA33
2.2.2.1Primary sources33
2.2.2.2Key data from primary sources34
2.2.2.3Key industry insights35
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION35
2.3MARKET SIZE ESTIMATION36
2.3.1BOTTOM-UP APPROACH36
2.3.1.1Approach 1: Company revenue estimation approach36
FIGURE 4BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH36
2.3.1.2Approach 3: Presentations of companies and primary interviews37
2.3.1.3Growth forecast37
2.3.1.4CAGR projections37
FIGURE 5CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS37
2.3.2TOP-DOWN APPROACH38
FIGURE 6WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH38
2.4MARKET BREAKDOWN AND DATA TRIANGULATION39
FIGURE 7DATA TRIANGULATION METHODOLOGY39
2.5MARKET SHARE40
2.6ASSUMPTIONS FOR THE STUDY40
3EXECUTIVE SUMMARY41
FIGURE 8WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION)41
FIGURE 9WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2022 VS. 2027 (USD MILLION)42
FIGURE 10WOUND CARE BIOLOGICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)42
FIGURE 11WOUND CARE BIOLOGICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION)43
4PREMIUM INSIGHTS44
4.1WOUND CARE BIOLOGICS MARKET OVERVIEW44
FIGURE 12INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS44
4.2WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT, 2022 VS. 202744
FIGURE 13BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 202744
4.3WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 202745
FIGURE 14ULCERS SEGMENT DOMINATES MARKET45
4.4WOUND CARE BIOLOGICS MARKET SHARE, BY END USER, 2022 VS. 202745
FIGURE 15HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS45
4.5WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES46
FIGURE 16ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD46
5MARKET OVERVIEW47
5.1INTRODUCTION47
5.2MARKET DYNAMICS47
FIGURE 17WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES47
5.2.1DRIVERS47
5.2.1.1Growing prevalence of diseases & conditions affecting wound healing capabilities47
5.2.1.1.1Growing geriatric population48
5.2.1.1.2Increasing prevalence of diabetes and target conditions48
FIGURE 18PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION,
2021 VS. 2045 (MILLION CASES)49
TABLE 1TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY49
TABLE 2LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS50
5.2.1.1.3Increasing number of surgical procedures across the globe50
5.2.1.1.4Increasing number of traumatic wounds51
TABLE 3PREVALENCE OF ROAD ACCIDENTS51
5.2.1.2Increasing incidence of burn injuries51
5.2.1.3Innovations in wound care biologics52
5.2.2MARKET RESTRAINTS52
5.2.2.1High cost of wound care biologic products52
TABLE 4AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018)52
5.2.2.2Risk of skin substitute failure53
TABLE 5COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)53
5.2.3OPPORTUNITIES54
5.2.3.1Growth potential of emerging economies54
TABLE 6STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC54
5.2.3.23D skin printing55
5.3IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET55
6WOUND CARE BIOLOGICS MARKET, BY PRODUCT57
6.1INTRODUCTION58
TABLE 7WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)58
TABLE 8WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)58
6.2BIOLOGICAL SKIN SUBSTITUTES58
TABLE 9KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET59
TABLE 10WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017–2020 (USD MILLION)59
TABLE 11WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021–2027 (USD MILLION)60
TABLE 12WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2017–2020 (USD MILLION)60
TABLE 13WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2021–2027 (USD MILLION)60
6.2.1HUMAN DONOR TISSUE-DERIVED PRODUCTS61
6.2.1.1High efficacy of human donor tissue-derived products to support market demand61
TABLE 14KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET61
TABLE 15HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION)62
TABLE 16HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION)62
6.2.2ACELLULAR ANIMAL-DERIVED PRODUCTS62
6.2.2.1Recognition of the importance of ECM in wound treatment has led to the development of acellular wound care biologics62
TABLE 17KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET63
TABLE 18ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION)63
TABLE 19ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION)64
6.2.3BIOSYNTHETIC PRODUCTS64
6.2.3.1Increased bioburden of infected wounds to stimulate market growth64
TABLE 20BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017–2020 (USD MILLION)64
TABLE 21BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021–2027 (USD MILLION)65
6.3TOPICAL AGENTS65
6.3.1INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH65
TABLE 22WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2017–2020 (USD MILLION)66
TABLE 23WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2021–2027 (USD MILLION)66
7WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE67
7.1INTRODUCTION68
TABLE 24WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)68
TABLE 25WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)68
7.1.1PRIMARY NOTES68
7.1.1.1Key industry insights68
7.2ULCERS69
TABLE 26WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2017–2020 (USD MILLION)69
TABLE 27WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2021–2027 (USD MILLION)70
TABLE 28WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2017–2020 (USD MILLION)70
TABLE 29WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2021–2027 (USD MILLION)70
7.2.1DIABETIC FOOT ULCERS71
7.2.1.1Increasing prevalence of diabetes to drive market growth71
TABLE 30WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2017–2020 (USD MILLION)71
TABLE 31WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2021–2027 (USD MILLION)72
7.2.2VENOUS ULCERS72
7.2.2.1Rising prevalence of obesity to drive market growth72
TABLE 32WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2017–2020 (USD MILLION)73
TABLE 33WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2021–2027 (USD MILLION)73
7.2.3PRESSURE ULCERS73
7.2.3.1Growing geriatric population to drive market growth73
TABLE 34WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2017–2020 (USD MILLION)74
TABLE 35WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2021–2027 (USD MILLION)74
7.2.4OTHER ULCERS75
TABLE 36COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS75
TABLE 37WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2017–2020 (USD MILLION)75
TABLE 38WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2021–2027 (USD MILLION)76
7.3SURGICAL & TRAUMATIC WOUNDS76
7.3.1RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH76
TABLE 39WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017–2020 (USD MILLION)77
TABLE 40WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021–2027 (USD MILLION)77
7.4BURNS77
7.4.1HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH77
TABLE 41WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2017–2020 (USD MILLION)78
TABLE 42WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2021–2027 (USD MILLION)79
8WOUND CARE BIOLOGICS MARKET, BY END USER80
8.1INTRODUCTION81
TABLE 43WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)81
TABLE 44WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)81
8.2HOSPITALS81
8.2.1INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH81
TABLE 45WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2017–2020 (USD MILLION)83
TABLE 46WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2021–2027 (USD MILLION)83
8.3AMBULATORY SURGERY CENTERS83
8.3.1GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT83
TABLE 47NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS84
TABLE 48PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US84
TABLE 49WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017–2020 (USD MILLION)84
TABLE 50WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2027 (USD MILLION)85
8.4BURN CARE CENTERS & WOUND CLINICS85
8.4.1RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH85
TABLE 51WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2017–2020 (USD MILLION)86
TABLE 52WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2021–2027 (USD MILLION)86
9WOUND CARE BIOLOGICS MARKET, BY REGION87
9.1INTRODUCTION88
TABLE 53WOUND CARE BIOLOGICS MARKET, BY REGION, 2017–2020 (USD MILLION)88
TABLE 54WOUND CARE BIOLOGICS MARKET, BY REGION, 2021–2027 (USD MILLION)88
9.2NORTH AMERICA89
FIGURE 19NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT90
TABLE 55NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)90
TABLE 56NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)91
TABLE 57NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)91
TABLE 58NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)91
TABLE 59NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)92
TABLE 60NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)92
TABLE 61NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)92
TABLE 62NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)93
9.2.1US93
9.2.1.1Increasing prevalence of diabetes and non-healing foot ulcers to support the uptake of wound biologics products93
TABLE 63US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)94
TABLE 64US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)94
TABLE 65US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)94
TABLE 66US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)95
TABLE 67US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)95
TABLE 68US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)95
9.2.2CANADA96
9.2.2.1Rising geriatric patient pool to drive market growth for wound biologics in Canada96
TABLE 69INCIDENCE OF DIABETES IN CANADA, 2019 VS. 202996
TABLE 70CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)97
TABLE 71CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)97
TABLE 72CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)97
TABLE 73CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)98
TABLE 74CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)98
TABLE 75CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)98
9.3EUROPE99
TABLE 76EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)99
TABLE 77EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)100
TABLE 78EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)100
TABLE 79EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)100
TABLE 80EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)101
TABLE 81EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)101
TABLE 82EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)101
TABLE 83EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)102
9.3.1UK102
9.3.1.1Increasing incidence of venous ulcers to drive the market growth102
TABLE 84UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)102
TABLE 85UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)103
TABLE 86UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)103
TABLE 87UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)103
TABLE 88UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)104
TABLE 89UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)104
9.3.2GERMANY104
9.3.2.1The large diabetic population in Germany supports the uptake of wound biologics in Germany104
TABLE 90GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)105
TABLE 91GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)105
TABLE 92GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)105
TABLE 93GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)106
TABLE 94GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)106
TABLE 95GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)106
9.3.3FRANCE107
9.3.3.1Rising government support to drive the demand for wound care biologics products in France107
TABLE 96FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)107
TABLE 97FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)107
TABLE 98FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)108
TABLE 99FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)108
TABLE 100FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)108
TABLE 101FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)109
9.3.4REST OF EUROPE109
TABLE 102ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)110
TABLE 103ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)110
TABLE 104ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)110
TABLE 105ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)111
TABLE 106ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)111
TABLE 107ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)111
9.4ASIA PACIFIC112
FIGURE 20ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT112
TABLE 108ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)113
TABLE 109ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)113
TABLE 110ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)113
TABLE 111ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)114
TABLE 112ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)114
TABLE 113ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)114
TABLE 114ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)115
TABLE 115ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)115
9.4.1CHINA115
9.4.1.1Increasing incidence of DFUs to propel the market growth115
TABLE 116CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)116
TABLE 117CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)116
TABLE 118CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)116
TABLE 119CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)117
TABLE 120CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)117
TABLE 121CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)117
9.4.2JAPAN118
9.4.2.1Growing geriatric population to drive the adoption of wound care products118
TABLE 122JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)118
TABLE 123JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)119
TABLE 124JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)119
TABLE 125JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)119
TABLE 126JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)120
TABLE 127JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)120
9.4.3INDIA120
9.4.3.1Growing medical tourism in the country to support the market growth for wound biologics120
TABLE 128INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)121
TABLE 129INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)121
TABLE 130INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)121
TABLE 131INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)122
TABLE 132INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)122
TABLE 133INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)122
9.4.4REST OF ASIA PACIFIC122
TABLE 134ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)123
TABLE 135ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)123
TABLE 136ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)124
TABLE 137ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)124
TABLE 138ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)124
TABLE 139ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)125
9.5LATIN AMERICA125
9.5.1RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH125
TABLE 140LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)125
TABLE 141LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)126
TABLE 142LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)126
TABLE 143LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)126
TABLE 144LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)127
TABLE 145LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)127
9.6MIDDLE EAST & AFRICA127
9.6.1SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS127
TABLE 146MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)128
TABLE 147MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)128
TABLE 148MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)128
TABLE 149MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)129
TABLE 150MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)129
TABLE 151MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)129
10COMPETITIVE LANDSCAPE130
10.1OVERVIEW130
10.2KEY PLAYER STRATEGIES/RIGHT TO WIN130
10.2.1OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET130
TABLE 152OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES130
10.3MARKET SHARE ANALYSIS132
10.3.1WOUND CARE BIOLOGICS MARKET132
FIGURE 21WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021)132
TABLE 153WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION132
10.4COMPANY EVALUATION QUADRANT133
10.4.1LIST OF EVALUATED VENDORS133
10.4.2STARS134
10.4.3EMERGING LEADERS134
10.4.4PERVASIVE PLAYERS134
10.4.5PARTICIPANTS134
FIGURE 22WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021135
10.5COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)135
10.5.1PROGRESSIVE COMPANIES135
10.5.2STARTING BLOCKS136
10.5.3RESPONSIVE COMPANIES136
10.5.4DYNAMIC COMPANIES136
FIGURE 23WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021136
10.6COMPETITIVE SCENARIO137
10.6.1PRODUCT LAUNCHES & REGULATORY APPROVALS137
TABLE 154KEY PRODUCT LAUNCHES & REGULATORY APPROVALS137
10.6.2DEALS137
TABLE 155KEY DEALS137
10.6.3OTHER DEVELOPMENTS138
TABLE 156OTHER DEVELOPMENTS138
11COMPANY PROFILES139
11.1KEY PLAYERS139
(Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats)*
11.1.1SMITH & NEPHEW PLC139
TABLE 157SMITH & NEPHEW PLC: BUSINESS OVERVIEW139
FIGURE 24SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)140
11.1.2ORGANOGENESIS INC.143
TABLE 158ORGANOGENESIS INC.: BUSINESS OVERVIEW143
FIGURE 25ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021)143
11.1.3MIMEDX146
TABLE 159MIMEDX: BUSINESS OVERVIEW146
FIGURE 26MIMEDX: COMPANY SNAPSHOT (2021)146
11.1.4INTEGRA LIFESCIENCES148
TABLE 160INTEGRA LIFESCIENCES: BUSINESS OVERVIEW148
FIGURE 27INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)149
11.1.5STRYKER CORPORATION151
TABLE 161STRYKER CORPORATION: BUSINESS OVERVIEW151
FIGURE 28STRYKER CORPORATION: COMPANY SNAPSHOT (2021)152
11.1.6MÖLNLYCKE HEALTH CARE AB154
TABLE 162MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW154
FIGURE 29MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021)155
11.1.7VERICEL CORPORATION157
TABLE 163VERICEL CORPORATION: BUSINESS OVERVIEW157
FIGURE 30VERICEL CORPORATION: COMPANY SNAPSHOT (2021)157
11.1.8ANIKA THERAPEUTICS, INC.158
TABLE 164ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW158
FIGURE 31ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021)159
11.1.9BIOVENTUS LLC160
TABLE 165BIOVENTUS LLC: BUSINESS OVERVIEW160
FIGURE 32BIOVENTUS LLC: COMPANY SNAPSHOT (2021)161
11.1.10ABBVIE INC.163
TABLE 166ABBVIE INC.: BUSINESS OVERVIEW163
FIGURE 33ABBVIE INC.: COMPANY SNAPSHOT (2021)163
11.1.11KERECIS165
TABLE 167KERECIS: BUSINESS OVERVIEW165
11.1.12MARINE POLYMER TECHNOLOGIES, INC.166
TABLE 168MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW166
11.2OTHER PLAYERS167
11.2.1MERAKRIS THERAPEUTICS167
TABLE 169MERAKRIS THERAPEUTICS: COMPANY OVERVIEW167
11.2.2POLYMEDICS INNOVATIONS GMBH167
TABLE 170POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW167
11.2.3FIBROHEAL WOUNDCARE PVT. LTD.168
TABLE 171FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW168
11.2.4ANAMAY BIOTECH, INC.168
TABLE 172ANAMAY BIOTECH, INC.: COMPANY OVERVIEW168
11.2.5VIRCHOW BIOTECH PRIVATE LIMITED169
TABLE 173VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW169
11.2.6MEDLINE INDUSTRIES, LP169
TABLE 174MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW169
11.2.7TIDES MEDICAL170
TABLE 175TIDES MEDICAL: COMPANY OVERVIEW170
11.2.8VISCUS BIOLOGICS LLC170
TABLE 176VISCUS BIOLOGICS LLC: COMPANY OVERVIEW170
11.2.9STABILITY BIOLOGICS171
TABLE 177STABILITY BIOLOGICS: COMPANY OVERVIEW171
11.2.10MTF BIOLOGICS171
TABLE 178MTF BIOLOGICS: COMPANY OVERVIEW171
11.2.11SKYE BIOLOGICS HOLDINGS, LLC172
TABLE 179SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW172
11.2.12ALLOSOURCE172
TABLE 180ALLOSOURCE: COMPANY OVERVIEW172
11.2.13SURGILOGIX173
TABLE 181SURGILOGIX: COMPANY OVERVIEW173
*Details on Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats might not be captured in case of unlisted companies.
12APPENDIX174
12.1DISCUSSION GUIDE174
12.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL177
12.3AVAILABLE CUSTOMIZATIONS179
12.4RELATED REPORTS179
12.5AUTHOR DETAILS180

Report Title: Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW